Bioventus INC 8-K filings

Bioventus Inc. announced second quarter 2026 financial results showing a 4% revenue increase and reaffirmed full-year guidance, while simultaneously initiating a review of strategic alternatives following unsolicited acquisition interest.

Bioventus Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Bioventus Inc. reiterates its 2026 financial guidance following the FDA's reclassification of non-invasive bone growth stimulators, expecting minimal impact from updated CMS reimbursement rates.

Bioventus Inc. announced a robust first quarter for 2026, with revenue up 7% and significant improvements in profitability and cash flow, leading to raised full-year guidance.

Bioventus Inc. announced robust fourth quarter and full-year 2025 financial results, driven by organic revenue growth and improved profitability, alongside optimistic 2026 guidance.

Bioventus Inc. announced the appointment of Ajay Dhankhar, PhD, Chief Corporate Development & Strategy Officer of Smith & Nephew plc, to its Board of Directors, effective November 14, 2025.

Bioventus Inc. reported third-quarter 2025 financial results with reported revenue comparable to last year at $138.7 million, while organic revenue grew 8%, and GAAP earnings per diluted share increased to $0.05 from a prior-year loss.

Bioventus Inc. reported a significant turnaround in net income and diluted EPS for Q2 2025, driven by strong organic revenue growth and new FDA clearances for nerve pain treatments.

Bioventus Inc.'s subsidiary has secured a new $400 million credit facility, including a $100 million revolving credit and a $300 million term loan, to refinance existing debt and support general corporate purposes.

Bioventus Inc. announced FDA 510(k) clearances for TalisMann and StimTrial, expanding its Peripheral Nerve Stimulation portfolio for chronic pain management.

Bioventus Inc. announced the successful election of all Class I director nominees and the ratification of Grant Thornton LLP as its independent auditor at its 2025 Annual Meeting of Stockholders.

Bioventus Inc. (Nasdaq: BVS) announced its Q1 2025 financial results, with a reported revenue decline of 4.3% but an organic revenue increase of 5.0%.

Bioventus reports accelerated sales growth, margin expansion, and increased cash flow for Q4 2024, along with full-year 2025 financial guidance indicating continued revenue growth and operating margin expansion.

Bioventus has completed the sale of its Advanced Rehabilitation business to Accelmed Partners for $25 million in cash, with potential earn-out payments of up to $20 million.

Bioventus Inc. announced a 15% increase in third-quarter revenue, driven by strong performance in Pain Treatments and Surgical Solutions, alongside improved profitability and cash flow.

Bioventus has agreed to sell its Advanced Rehabilitation business to Accelmed Partners for a total consideration of $45 million, including potential earn-out payments.

Bioventus announced a 10.3% increase in second-quarter revenue, driven by double-digit organic growth in Pain Treatments and Surgical Solutions, and raised its full-year 2024 financial guidance.

Bioventus Inc. has agreed to a $15.25 million settlement to resolve a class action lawsuit, with a portion expected to be covered by insurance.

Bioventus Inc. has amended its Stockholders Agreement to phase out its classified board structure, moving towards annual elections for all directors.

Bioventus Inc. has declassified its board of directors, moving to annual elections, and adopted amended bylaws following shareholder approval at its 2024 annual meeting.

Bioventus reported strong first-quarter results with significant revenue growth and increased profitability, leading to an upward revision of its full-year 2024 financial guidance.

Bioventus reported a strong fourth quarter in 2023 with accelerated sales growth and improved profitability, alongside the appointment of a new CEO and positive financial guidance for 2024.

Bioventus Inc. has entered into an amendment to its credit agreement, modifying financial covenant requirements and adding liquidity maintenance provisions.

Bioventus Inc.'s board approved the immediate acceleration of vesting for all outstanding equity awards of former Interim CEO Anthony P. Bihl III, effective January 9, 2024.